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Introduction
There is good news to report. I list below a number of sig-
nificant advances in breast cancer metastasis research.
Each of these shifts has the potential to influence transla-
tional research (ie drug development, preclinical studies
and clinical trials). I offer my thanks to the authors who
contributed the accompanying reviews.
The barn door has not been left open!
Metastatic colonization as a translational target
The number of clinicians whose eyes glaze over as metas-
tasis researchers dutifully recite the many steps of the
metastatic process, and go on to examine tumor cell inva-
sion in minute detail, signals either that we give boring lec-
tures or that we have evoked the ‘so what?’ response.
Those who would favor the latter response might state
that, even for the greater than 90% of patients without
detectable distant metastases at surgery, it remains possi-
ble that tumor cells have already invaded out of the
primary tumor and are sitting contentedly in distant sites
undetected. Only ‘growth’ and angiogenesis remain. Why
study metastasis when it may be virtually complete by the
time the patient walks into the clinic? Has the barn door
been left open? Should we all drop our experiments and
switch to antiangiogenesis projects?
Two reviews in this series have addressed this critical
question, and arrived at similar answers. Investigators from
Dr Ann Chambers’ laboratory have watched it all happen.
She and others have tagged tumor cells and watched them
metastasize to the livers and lungs of experimental animals
using in vivo videomicroscopy [1]. She reports that the
clinicians are partially correct; both metastatically compe-
tent and poorly metastatic cell lines arrive at the metastatic
site and extravasate at high frequencies. What separates
the cells with high from those with low metastatic potential
is their ability to colonize in that distant site. Differences in
metastatic colonization potential are observable at the
micrometastatic stages, before angiogenesis is a rate-limit-
ing step. In addition to Dr Chambers’ in vivo work, other
researchers using nonbreast cancer cell lines have recently
identified different points of metastatic blockade in distant
organs, such as metastatic colonization attached to lung
endothelium [2]. Both findings, however, point to coloniza-
tion at the secondary site as the metastasis-limiting point.
Thus, intravital videomicroscopy efforts have confirmed
metastatic colonization as a critical limiting step, and cur-
rently suggest heterogeneity in its mechanism.
These studies have several interesting implications. What
is the significance of the detection of isolated cancer cells
in metastatic sites? How is metastatic colonization of a
distant site different from that of primary tumor growth,
and does it represent an understudied but valuable trans-
lational target? What are we learning when we test lead
agents in xenograft model systems, and measure changes
in primary tumor size?
Dr Danny Welch and colleagues, in their review [3], report
a similar conclusion from a completely different line of
investigation. The investigators study metastasis-suppres-
sor genes, which suppress metastasis but not primary
tumor growth, upon injection of transfected cells into
experimental animals. There is a growing and vibrant litera-
ture on these genes, which is reviewed. Intriguingly, the
mechanism of action of many of the metastasis-suppressor
genes is unknown (ie not among the traditional adhesion,
protease and motility factors studied in invasion). Although
this has represented a ‘kiss of death’ to editors and study
sections, emerging evidence from multiple metastasis-sup-http://breast-cancer-research.com/content/2/6/396
pressor genes suggests that it may represent a strength,
because it supports the hypothesis that these genes ‘work’
by a different mechanism. Studies in breast and prostate
carcinoma model systems indicate that tumor cells from
metastasis suppressed kai1 or kiss transfectants, as well
as their and metastatically competent control transfectants,
arrived in the distant organ at comparable frequencies and
with equivalent viabilities. What distinguished metastatic
competence was the ability to complete nonangiogenesis-
dependent colonization in the distant site.
That two different fields of inquiry have developed similar
conclusions is noteworthy. I propose that the metastasis
field focus attention on metastatic colonization as a dis-
tinct, translationally important facet of breast cancer pro-
gression. Although angiogenesis at the distant site is
undoubtedly clinically important, the work summarized
above demonstrates that nonangiogenic processes inher-
ent in metastatic colonization also exist and are amenable
to translational development.
What is metastatic colonization? How is it different from
primary tumor growth? The literature implies that metasta-
tic colonization is more than proliferation, and includes
facets such as dormancy, apoptosis, novel sets of
cell–cell and cell–tissue interactions, altered responsive-
ness to paracrine factors, etc. The discovery of mkk4 as a
prostate cancer metastasis-suppressor gene suggests
that the stress kinase signal transduction pathway may be
germane to metastatic colonization [4], and we await con-
firmation of this trend in breast cancer metastasis.
Perhaps a distinguishing factor in metastatic colonization
is the adaptive response to the stress of being on foreign
‘soil’, and that specific signal transduction pathways will
be involved. In nm23-transfected breast carcinoma cells,
the ubiquitous soft agar anchorage-independent growth
assay was used as an imperfect measure of metastatic
colonization [5]. Metastasis-suppressed nm23 transfec-
tants colonized poorly in soft agar, and remained unre-
sponsive to the addition of transforming growth factor-b,
whereas metastatically competent control transfectants
were more proficient at colonization and were stimulated
by transforming growth factor-b. This switch in responsive-
ness to a widely available cytokine may be part of the
stress response to foreign ‘soil’. The progress of this new
field of inquiry will undoubtedly depend on the develop-
ment of in vitro model systems that accurately replicate
the in vivo process, as well as continued development of
in vivo model systems to enable the visualization, quantita-
tion, and characterization of micrometastatic cells.
Finally, we need to acknowledge that most of our breast
cancer metastasis model systems rely on metastases to
the draining lymph nodes and lungs. An emerging litera-
ture is reviewed elsewhere on metastasis studies to the
bone [6,7], and attempts have been made to optimize
models for breast cancer metastasis to the brain [8,9] and
other sites [10]. It is conceivable that we may obtain differ-
ent answers to our metastatic colonization questions as
these relevant models evolve.
Are there nonendothelial targets for
angiogenesis in breast cancer?
Recently the laboratories of Drs Mary Hendrix and Robert
Folberg have put forth a hypothesis in ocular melanoma,
which proposes that aggressive tumor cells can form
extracellular matrix (ECM) channels that contain blood and
may augment endothelial-derived angiogenesis [11–13].
This hypothesis has generated discussion and contro-
versy, but areas of concordance appear in the field. Does
it apply to breast cancer?
A brief digression into uveal melanoma is required. The
team of Drs Hendrix and Folberg used uveal melanomas,
which lack lymphatics and therefore present a simpler
system for study. A periodic acid–Schiff immunohisto-
chemical stain identified nonendothelial channels that
appeared delimited by ECM and ultimately melanoma
cells, and which contained erythrocytes. It remains contro-
versial whether traditional endothelial-derived capillaries
also service these tumor cells, with opinions based on the
stain used, the observer, and the intratumoral location of
the observation. The looping patterns have also been pro-
posed to represent ECM-surrounding nests of tumor cells
[11,13]. The overall significance of these looping struc-
tures is unknown, but of high interest. Do they represent
1%, 10% or 100% of bloodflow? Do they generally
conduct blood, or is this the result of hemorrhage in
surgery [14]? Affiliated in vitro experiments suggest addi-
tional possibilities; culture of aggressive, but not nonag-
gressive melanoma cell lines in ECM resulted in patterned,
ECM-channel network formation. Dr Mina Bissell [15]
noted that the time course of channel formation, and its
localization inside the ECM, are distinct from the rapidly
formed networks that many of us observe when cells are
plated onto matrigel. Array analysis of the channel-forming
melanoma cells revealed that they expressed two sets of
genes of interest: genes of the ‘interconverted’ pheno-
types, suggesting a dual differentiation or redifferentiation
of the melanomas expressing both epithelial and mes-
enchymal phenotypes; and genes associated with tradi-
tional angiogenesis. The latter observation also prompts
us to ask what exactly we are detecting when we stain for
factor VIII, or other ‘endothelial’ proteins.
The accompanying review by Dr Mary Hendrix et al [16]
now expands this hypothesis to breast cancer using the in
vitro culture system. We anxiously await in vivo evidence
for or against this hypothesis in breast cancer, because it
will impact on our thinking on clinical antiangiogenic strate-
gies. Will endothelial based therapies ‘work’ if alternate
vascular systems exist? Do these new vascular systemsBreast Cancer Research    Vol 2 No 6 Steeg
represent additional therapeutic targets? These questions
will undoubtedly be addressed using tagged cell lineages
in animal models, and we invite involved researchers to
consider the breast cancer models available.
The heterogeneity of breast cancer:
inflammatory breast cancer
So much of our cancer research work is delineated by the
cell lines and mouse systems available, and metastasis
research is no exception. It is with great pleasure that we
read a review from Dr Sofia Merajver and colleagues [17]
on recent progress in inflammatory breast cancer. This
cancer type occurs rarely, but is exceptionally aggressive.
It is defined both clinically and pathologically, with tumor
cell infiltration of the dermal lymphatics leading to
inflamed appearing skin as a hallmark. Cell lines from
inflammatory breast tumors were established by Dr Steve
Ethier and colleagues [18], and a xenograft mouse model
system was reported by Alpaugh et al [19]. Using the cell
lines, Dr Merajver reports that relatively unstudied molec-
ular alterations occur in inflammatory breast cancer, and
her focus is on RhoC GTPase in signal transduction and
an insulin-like growth factor-binding protein. These find-
ings advance the field toward the day when a diagnosis
of inflammatory breast cancer signals the patient’s entry
into molecularly defined clinical trials of treatments that
are specific for this disease.
The impressive results reviewed herein in inflammatory
breast cancer highlight the importance of investigation
into the many subtypes of aggressive breast cancer. A
corollary of this observation is our need for funding of
model system and cell line development to facilitate these
critical studies.
The number crunch: will mathematics contribute
meaningfully to metastasis research?
This is where the molecular biologists’ eyes glaze over. Is
metastasis too complex, heterogeneous, and unstable to
model mathematically? Similar arguments were forwarded
to predict that molecular genetic alterations would not be
instructive to metastasis research years ago.
Dr Susan Clare and colleagues [20] have reviewed the
recent progress in the field of mathematical modeling with
respect to breast cancer natural history, its metastatic initi-
ation, the effect of surgery, tumor dormancy, and the effec-
tiveness of chemotherapy. Quantitative predictive
approaches should be familiar to the cell biologist who
tests the metastatic potential of cell lines in mice and the
pharmacologist who performs in vivo testing of lead
agents, as well as the clinician who is concerned with the
dosing and timing of drugs. All three types of research,
and not just the latter, need to be evaluated and under-
stood mathematically. At a minimum we should be able to
judge which preclinical models best fit the human situa-
tion. Optimally, we continue to refine our modeling so that
reasonable predictions can improve the development of in
vivo experiments and clinical trials.
Conclusion
The tumor metastasis field holds great promise for translat-
ing our developing understanding of the molecular and
signal transduction pathways underlying aggressive cell
behavior to the clinic. The obstacles to such advances, in
my opinion, include: (a) the availability of model systems that
reproduce the heterogeneity of human disease; (b) a hesi-
tancy to test a pathway in a human tumor cohort study, to
see if a trend observed in a cell line actually correlates with
aggressive clinical course; and (c) the need for better inter-
actions between bench researchers and industry, where
many lead agents are under development. The breast
cancer field has been invigorated by the participation of
cancer survivors/advocates, and their message is germane:
it is not enough to discover an interesting pathway. How will
it lead to the treatment of metastatic disease?
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